[go: up one dir, main page]

AR063155A1 - Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos - Google Patents

Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos

Info

Publication number
AR063155A1
AR063155A1 ARP070104427A ARP070104427A AR063155A1 AR 063155 A1 AR063155 A1 AR 063155A1 AR P070104427 A ARP070104427 A AR P070104427A AR P070104427 A ARP070104427 A AR P070104427A AR 063155 A1 AR063155 A1 AR 063155A1
Authority
AR
Argentina
Prior art keywords
angiotensin
treatment
antagonist
receptor
cats
Prior art date
Application number
ARP070104427A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR063155A1 publication Critical patent/AR063155A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método de profilaxis o tratamiento de enfermedades generalizadas en gatos, en el que el método que comprende la administracion de una cantidad terapéuticamente eficaz de antagonista (sartán) del receptor 1 (AT-1) de angiotensina II a un gato necesitado de dicho tratamiento. Reivindicacion 1: Utilizacion de un antagonista (sartán) del receptor 1 (AT-1) de angiotensina II para la preparacion de una composicion farmacéutica que comprende una cantidad terapéuticamente eficaz de dicho antagonista del receptor 1 (AT-1) de angiotensina II para el tratamiento de una enfermedad generalizada en gatos. Reivindicacion 4: La utilizacion segun una cualquiera de las reivindicaciones 1 a 3, en la que el antagonista del receptor 1 (AT-1) de angiotensina II se selecciona del grupo consistente en: candesartán, eprosartán, irbesartán, losartán, tasosartán, telmisartán, valsartán, y una de sus sales farmacéuticamente aceptable. Reivindicacion 8: La utilizacion segun una cualquiera de las reivindicaciones 1 a 7, en la que la composicion farmacéutica que comprende la cantidad terapéuticamente eficaz del antagonista del receptor 1(AT-1) de angiotensina II se administra junto con al menos otro fármaco a un gato necesitado de dicho tratamiento. Reivindicacion 9: La utilizacion segun la reivindicacion 8, en la que el otro fármaco se selecciona del grupo consistente en bloqueadores del (canal del Ca (p.ej. Amlodipina), beta-bloqueadores (p. ej., Atenolol, Carvediol), agentes cardiotonicos sensibilizantes al Ca (p. ej., Pimobendan, Levosimendan), inhibidores II actuales selectivos (es decir, Cilobradina, Ivabradina), inhibidores de ACE (p. ej., ramipril, benazepril, enalapril); fármacos contra la obesidad (tales como derivados de Anfetamina, Sibutramina, Orlistat, Rimonabat).
ARP070104427A 2006-10-06 2007-10-09 Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos AR063155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121905A EP1908469A1 (en) 2006-10-06 2006-10-06 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats

Publications (1)

Publication Number Publication Date
AR063155A1 true AR063155A1 (es) 2008-12-30

Family

ID=37744125

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104427A AR063155A1 (es) 2006-10-06 2007-10-09 Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos

Country Status (25)

Country Link
US (5) US8772278B2 (es)
EP (5) EP1908469A1 (es)
JP (5) JP5425631B2 (es)
KR (2) KR101529541B1 (es)
CN (6) CN114344293B (es)
AR (1) AR063155A1 (es)
BR (4) BRPI0718041A2 (es)
CA (1) CA2665435C (es)
CL (2) CL2007002897A1 (es)
CO (1) CO6180425A2 (es)
CY (2) CY1114266T1 (es)
DK (4) DK2420231T3 (es)
ES (4) ES2425482T3 (es)
HR (1) HRP20130696T1 (es)
HU (4) HUE027280T2 (es)
LU (1) LU92282I2 (es)
MX (4) MX360148B (es)
NL (1) NL300616I2 (es)
NZ (3) NZ597648A (es)
PL (4) PL2086535T3 (es)
PT (1) PT2086535E (es)
SI (1) SI2086535T1 (es)
TW (3) TWI539949B (es)
WO (1) WO2008040774A2 (es)
ZA (1) ZA200901218B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
CN102283832B (zh) * 2011-09-09 2013-04-10 南京正宽医药科技有限公司 一种预防或治疗高血压肥胖患者的药物组合物及用途
AU2013262438B2 (en) * 2012-05-18 2017-03-16 Luoda Pharma Limited Liquid formulation
DE102012018903A1 (de) 2012-09-26 2014-03-27 Elisabeth Kurth Brustglocke für die manuelle Laktation von Milch aus der weiblichen Brust
CN105233288A (zh) * 2015-09-28 2016-01-13 青岛云天生物技术有限公司 一种治疗或预防肥胖型高血压的药物组合物及其用途
JP6800633B2 (ja) * 2016-07-04 2020-12-16 株式会社カネカ 非ヒト動物において腎機能の低下を抑制する方法
NZ759782A (en) * 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
EP3996709A1 (en) * 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
JPWO2022145443A1 (es) * 2020-12-28 2022-07-07
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1023027B (de) 1953-07-10 1958-01-23 Hoffmann La Roche Verfahren zur Herstellung von Polyendialdehyden
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en) 1981-08-03 1984-05-15 Ici Americas Inc. Maltitol containing gel base systems
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
TW201738B (es) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
ATE181830T1 (de) 1992-04-13 1999-07-15 Zeneca Ltd Angiotensin-ii-antagonisten gegen erkrankungen; die mit einer eingeschränkten; neuronalen leitungsgeschwindigkeit verbunden sind, insbesondere diabetische neuropathie
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
JP3883205B2 (ja) 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
CA2214143A1 (en) * 1995-04-07 1996-10-10 Marc De Gasparo Combination compositions containing benazepril or benazeprilat and valsartan
DE69712338T2 (de) * 1996-06-24 2002-11-07 Merck & Co., Inc. Zusammensetzung auf basis von enalapril und losartan
KR20010086245A (ko) 1998-03-04 2001-09-10 다케다 야쿠힌 고교 가부시키가이샤 Ａⅱ 길항제용 서방성 제제, 그것의 제조 및 용도
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1329217A4 (en) 2000-10-06 2007-04-04 Takeda Pharmaceutical Solid preparations
CA2445913A1 (en) * 2001-05-14 2003-10-29 Merck & Co., Inc. Method of treatment
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
PL373202A1 (en) * 2002-05-17 2005-08-22 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
EP1578360A4 (en) * 2002-08-28 2009-10-21 Curis Inc JOINT ADMINISTRATION OF MORPHOGENES AND ANGIOTENSIN ENZYME CONVERTING INHIBITORS FOR THE TREATMENT OF CHRONIC RENAL FAILURE
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
WO2005123070A1 (en) * 2004-06-09 2005-12-29 Fibrogen, Inc. Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
CN1602960A (zh) * 2004-07-23 2005-04-06 海南国栋药物研究所有限公司 一种防治心脑血管病及糖尿病等代谢综合症的复合制剂
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
EA013053B1 (ru) * 2004-11-05 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Двуслойная таблетка, содержащая телмисартан и амлодипин
CN1813707A (zh) * 2004-12-01 2006-08-09 鲁南制药集团股份有限公司 用于治疗高血压的含有单硝酸异山梨酯的药物组合物
US20070026026A1 (en) 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1970053A1 (en) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan

Also Published As

Publication number Publication date
ES2425482T3 (es) 2013-10-15
EP2086535B1 (en) 2013-05-22
HUS1800044I1 (hu) 2018-12-28
CY2013037I1 (el) 2015-11-04
ES2567041T3 (es) 2016-04-19
US9585873B2 (en) 2017-03-07
CN114344293A (zh) 2022-04-15
JP2017122115A (ja) 2017-07-13
NZ609533A (en) 2014-08-29
MX2009002340A (es) 2009-03-23
ZA200901218B (en) 2010-03-31
EP2420232A3 (en) 2012-05-02
JP5425631B2 (ja) 2014-02-26
EP2420232A2 (en) 2012-02-22
JP6337170B2 (ja) 2018-06-06
CN109125730A (zh) 2019-01-04
HRP20130696T1 (hr) 2013-09-30
KR20140088601A (ko) 2014-07-10
MX360148B (es) 2018-10-24
DK2086535T3 (da) 2013-07-22
EP2420231A2 (en) 2012-02-22
CN102512678A (zh) 2012-06-27
EP2420232B1 (en) 2016-01-06
HUE027280T2 (en) 2016-09-28
EP2420233A2 (en) 2012-02-22
US9949954B2 (en) 2018-04-24
EP2420233A3 (en) 2012-04-18
PL2420232T3 (pl) 2016-06-30
CL2012001349A1 (es) 2012-10-12
EP2420233B1 (en) 2016-01-13
CL2007002897A1 (es) 2008-03-07
PT2086535E (pt) 2013-08-22
BR122013019535A2 (pt) 2015-07-14
US9308197B2 (en) 2016-04-12
AU2007304216A1 (en) 2008-04-10
TW201402115A (zh) 2014-01-16
TW201332547A (zh) 2013-08-16
CN101522191A (zh) 2009-09-02
JP2010505796A (ja) 2010-02-25
US20180193317A1 (en) 2018-07-12
CA2665435A1 (en) 2008-04-10
NL300616I2 (es) 2016-06-01
DK2420231T3 (en) 2016-04-11
JP2013216709A (ja) 2013-10-24
MX360147B (es) 2018-10-24
BRPI0718041A2 (pt) 2015-05-12
TWI539950B (zh) 2016-07-01
KR101456151B1 (ko) 2014-11-04
CA2665435C (en) 2016-03-29
CN102580095A (zh) 2012-07-18
LU92282I2 (fr) 2013-11-19
NZ597648A (en) 2013-05-31
NZ576109A (en) 2012-02-24
BR122013019533A2 (pt) 2015-07-14
CN105148272A (zh) 2015-12-16
BR122013019534A2 (pt) 2015-07-14
WO2008040774A2 (en) 2008-04-10
ES2565519T3 (es) 2016-04-05
KR20090080954A (ko) 2009-07-27
JP5899165B2 (ja) 2016-04-06
US8772278B2 (en) 2014-07-08
TW200831078A (en) 2008-08-01
US20170128423A1 (en) 2017-05-11
CN114344293B (zh) 2024-04-19
MX360150B (es) 2018-10-24
AU2007304216B2 (en) 2013-06-13
PL2086535T3 (pl) 2013-10-31
JP2013216708A (ja) 2013-10-24
CO6180425A2 (es) 2010-07-19
TWI539949B (zh) 2016-07-01
HUE027399T2 (en) 2016-09-28
US20130190373A1 (en) 2013-07-25
DK2420232T3 (en) 2016-03-07
ES2562182T3 (es) 2016-03-02
EP2420231A3 (en) 2012-04-11
WO2008040774A3 (en) 2008-07-10
HUS1300062I1 (hu) 2013-11-28
US10357479B2 (en) 2019-07-23
PL2420233T3 (pl) 2016-07-29
KR101529541B1 (ko) 2015-06-17
CY1114266T1 (el) 2015-11-04
EP1908469A1 (en) 2008-04-09
CN101522191B (zh) 2012-05-16
PL2420231T3 (pl) 2016-07-29
EP2420231B1 (en) 2016-01-13
TWI415605B (zh) 2013-11-21
CY2013037I2 (el) 2015-11-04
CN102580095B (zh) 2015-12-09
US20140288138A1 (en) 2014-09-25
SI2086535T1 (sl) 2013-09-30
JP6151123B2 (ja) 2017-06-21
LU92282I9 (es) 2019-01-17
EP2086535A2 (en) 2009-08-12
DK2420233T3 (en) 2016-04-11
US20080146543A1 (en) 2008-06-19
JP2016094436A (ja) 2016-05-26

Similar Documents

Publication Publication Date Title
AR063155A1 (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos
Michel et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
RU2020113612A (ru) Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
EA201690033A3 (ru) Морфинановые соединения
MX339805B (es) Compuestos organicos.
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
MX2012004848A (es) Compuestos heterociclicos triciclicos.
JP2018507244A5 (es)
CY1110947T1 (el) Προϊον συνδυασμου ενος ανταγωνιστη ή ενος αναστροφου αγωνιστη του υποδοχεως η3 της ισταμινης με ενα αντι-ψυχωτικο ή ένα αντι-καταθλιπτικο παραγοντα, και η χρηση αυτου για την παρασκευη φαρμακου το οποιο προλαμβανει τις ανεπιθυμητες επιδρασεις ψυχοτροπων φαρμακων
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2013006715A (es) Derivado de pirazol.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
EP2607363A4 (en) CONDENSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONISTS
ECSP10010428A (es) Derivados de indazol
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
JP2012502915A5 (es)
EA201170256A1 (ru) Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
RU2010101303A (ru) Замещенные (оксазолидинон-5-ил-метил)-2-тиофен-карбоксамиды и их применение в сфере свертывания крови
EA200900742A1 (ru) Производные аминохиназолина с понижающими тромбоциты свойствами

Legal Events

Date Code Title Description
FB Suspension of granting procedure